Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4831 in heart failure with preserved or mildly reduced ejection fraction
NL-OMON49300Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and heart failure with mid-range ejection fraction (HFmrEF) comparing AZD4831 with Placebo (2 arms). Primary endpoint: Target engagement. Started Sep 2019; status: active, not recruiting.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on NL-OMON49300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49300.